Furthermore, in breast cancer models, loss of E-cadherin, and the subsequent activation of IGF1R signaling, results in increased sensitivity to dual IGF1R/Insulin receptor inhibitors, and AKT inhibitors that target downstream receptor pathway activation, even in the presence of activating PIK3CA mutations [35,37]. The gene discussed is IGF1R; the disease is breast cancer.